{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036486","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-08-07T12:30:17+00:00","discovered_at":"2026-08-07T12:35:03.655900+00:00","generated_at":"2026-08-07T12:35:33.507799+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY","bullets":["Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.","CyPath Lung test volume +216% YoY; H1 revenue from test +159% to ~$835k; 1,097 reports vs 390.","Cash and equivalents $2.4M at June 30, 2026 vs $6.4M at Dec 31, 2025; completed $3.2M public offering in June.","Pipeline: asthma/COPD diagnostics and skin cancer therapeutics; longitudinal trial at 11 sites incl. VA.","Physician offices ordering test up 122%; existing clients' orders +71% H1 YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036486","json":"https://secwatch.observer/filing/0001493152-26-036486.json","markdown":"https://secwatch.observer/filing/0001493152-26-036486.md","text":"https://secwatch.observer/filing/0001493152-26-036486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/0001493152-26-036486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T12:35:33.507799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}